
Alzheimer's Disease Diagnostics & Therapeutics Market by Product (Diagnostics, Therapeutics), Disease Stage (Early, Moderate, Severe), End-User - Global Forecast 2024-2030
Description
Alzheimer's Disease Diagnostics & Therapeutics Market by Product (Diagnostics, Therapeutics), Disease Stage (Early, Moderate, Severe), End-User - Global Forecast 2024-2030
The Alzheimer's Disease Diagnostics & Therapeutics Market size was estimated at USD 6.75 billion in 2023 and expected to reach USD 7.26 billion in 2024, at a CAGR 8.00% to reach USD 11.57 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Alzheimer's Disease Diagnostics & Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alzheimer's Disease Diagnostics & Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Alzheimer's Disease Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., AC Immune SA, Alector, Inc., Alzheon, Inc., Amylyx Pharmaceuticals, Inc., AstraZeneca PLC, Biogen Inc., BioXcel Therapeutics Inc., Bristol-Myers Squibb Company, Codiak BioSciences, Cognoptix Inc., Corium Inc., Denali Therapeutics Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Grifols, S.A., H. Lundbeck A/S, Lexeo Therapeutics, Inc., Luye Pharma Group, Merz Pharma GmbH & Co. KGaA, MODAG GmbH, Muna Therapeutics, Novartis AG, Pfizer, Inc., Siemens Healthineers AG, Supernus Pharmaceuticals, Inc., TauRx Therapeutics Ltd., VectorY Therapeutics, Vigil Neuroscience, Inc., Voyager Therapeutics, Inc., and Zydus Lifesciences Limited.
Market Segmentation & Coverage
This research report categorizes the Alzheimer's Disease Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Product
Diagnostics
Biomarker
Cholinesterase Inhibitors
Early
Academic Research Institutes
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Alzheimer's Disease Diagnostics & Therapeutics Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alzheimer's Disease Diagnostics & Therapeutics Market?
- What are the technology trends and regulatory frameworks in the Alzheimer's Disease Diagnostics & Therapeutics Market?
- What is the market share of the leading vendors in the Alzheimer's Disease Diagnostics & Therapeutics Market?
- Which modes and strategic moves are suitable for entering the Alzheimer's Disease Diagnostics & Therapeutics Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
190 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Alzheimer's Disease Diagnostics & Therapeutics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing geriatric population and rising incidence of Alzheimer’s disease globally
- 5.1.1.2. Increasing use of biomarkers in Alzheimer's disease diagnosis and drug development
- 5.1.1.3. Availability of large number of Alzheimer’s disease drugs in pipeline
- 5.1.2. Restraints
- 5.1.2.1. Concerns associated with difficulties with early detection of Alzheimer’s disease
- 5.1.3. Opportunities
- 5.1.3.1. Increasing focus on development of novel Alzheimer’s disease diagnostics and therapeutics
- 5.1.3.2. Rising government support for Alzheimer's diagnosis and drug development
- 5.1.4. Challenges
- 5.1.4.1. High failure rates of clinical studies related to Alzheimer’s disease diagnosis and treatment
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Alzheimer's Disease Diagnostics & Therapeutics Market, by Product
- 6.1. Introduction
- 6.2. Diagnostics
- 6.3.1. Biomarker
- 6.3.2. Cognitive Assessment
- 6.3.3. Imaging Technologies
- 6.3. Therapeutics
- 6.4.1. Cholinesterase Inhibitors
- 6.4.2. N-Methyl-D-Aspartate Receptor Antagonists
- 7. Alzheimer's Disease Diagnostics & Therapeutics Market, by Disease Stage
- 7.1. Introduction
- 7.2. Early
- 7.3. Moderate
- 7.4. Severe
- 8. Alzheimer's Disease Diagnostics & Therapeutics Market, by End-User
- 8.1. Introduction
- 8.2. Academic Research Institutes
- 8.3. Diagnostics Laboratories
- 8.4. Hospitals & Clinics
- 9. Americas Alzheimer's Disease Diagnostics & Therapeutics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Alzheimer's Disease Diagnostics & Therapeutics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Alzheimer's Disease Diagnostics & Therapeutics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Abbvie Inc.
- 13.1.2. AC Immune SA
- 13.1.3. Alector, Inc.
- 13.1.4. Alzheon, Inc.
- 13.1.5. Amylyx Pharmaceuticals, Inc.
- 13.1.6. AstraZeneca PLC
- 13.1.7. Biogen Inc.
- 13.1.8. BioXcel Therapeutics Inc.
- 13.1.9. Bristol-Myers Squibb Company
- 13.1.10. Codiak BioSciences
- 13.1.11. Cognoptix Inc.
- 13.1.12. Corium Inc.
- 13.1.13. Denali Therapeutics Inc.
- 13.1.14. Eisai Co., Ltd.
- 13.1.15. Eli Lilly and Company
- 13.1.16. F. Hoffmann-La Roche AG
- 13.1.17. Grifols, S.A.
- 13.1.18. H. Lundbeck A/S
- 13.1.19. Lexeo Therapeutics, Inc.
- 13.1.20. Luye Pharma Group
- 13.1.21. Merz Pharma GmbH & Co. KGaA
- 13.1.22. MODAG GmbH
- 13.1.23. Muna Therapeutics
- 13.1.24. Novartis AG
- 13.1.25. Pfizer, Inc.
- 13.1.26. Siemens Healthineers AG
- 13.1.27. Supernus Pharmaceuticals, Inc.
- 13.1.28. TauRx Therapeutics Ltd.
- 13.1.29. VectorY Therapeutics
- 13.1.30. Vigil Neuroscience, Inc.
- 13.1.31. Voyager Therapeutics, Inc.
- 13.1.32. Zydus Lifesciences Limited
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
- FIGURE 2. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
- FIGURE 7. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
- FIGURE 8. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2030 (%)
- FIGURE 10. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 12. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.